Drugs / 68Ga-FAP-RGD
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05515783 | May 2022 → May 2024 | neoplasm | First Affiliated Hospital of Fujian Medical University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-FAP-RGD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05515783 ↗ |
| Known as | LNC1007 | “PURPOSE: This head-to-head comparison study aimed to compare the performance of [68Ga]Ga-FAPI-RGD (LNC1007) and 2-[18F]FDG PET/CT in the evaluation of patients with metastatic...” PMID 39404790 ↗ Oct 2024 |
| Modality | Diagnostic / imaging agent | “As an new dual targeting PET radiotracer, 68Ga-FAP-RGD is promising as an excellent imaging agent applicable to various cancers.” NCT05515783 ↗ |
| Route | Intravenous | “The dose will be 4-7mCi given intravenously.” NCT05515783 ↗ |